Lantheus taps four new execs
Lantheus Medical Imaging has hired four new executives: David Pendleton as senior director, PET perfusion agent; Alexander Ehlgen, MD, PhD, as associate medical director of Definity; Daniel Griffin as director of compensation and benefits; and Erin Boyer as senior business partner and director of human resources.
Pendleton comes from CHS Consulting, where he engaged with therapeutic and diagnostic imaging companies for business development, marketing and marketing management. Prior to CHS, he served as director of marketing and clinical operations for Theseus Imaging. From 1981 to 2002, Lantheus said that Pendleton held positions at DuPont Pharmaceuticals, including senior marketing director of Definity, and he was the brand director of Cardiolite prior to its acquisition by Bristol-Myers Squibb in 2001.
Prior to joining Lantheus, Ehlgen served as senior director of clinical affairs for start-up biotechnology company Point Biomedical. In this position, Lantheus said that he was responsible for the clinical development of an ultrasound imaging agent to diagnose coronary artery disease.
Griffin joins Lantheus as director, compensation and benefits from Novartis Vaccines and Diagnostics, where he served as director of U.S. compensation and benefits. At Novartis Vaccines and Diagnostics, he led the transition from the Chiron compensation programs to the Novartis structure, according to the North Billerica, Mass.-based Lantheus.
During her time at Dyax as the director of human resources, Boyer was responsible for administration, benefits and compensation, performance management, employee relations and recruiting, according to Lantheus. Prior to joining Dyax, she held various human resources management positions at Nuance and Avicon.
Pendleton comes from CHS Consulting, where he engaged with therapeutic and diagnostic imaging companies for business development, marketing and marketing management. Prior to CHS, he served as director of marketing and clinical operations for Theseus Imaging. From 1981 to 2002, Lantheus said that Pendleton held positions at DuPont Pharmaceuticals, including senior marketing director of Definity, and he was the brand director of Cardiolite prior to its acquisition by Bristol-Myers Squibb in 2001.
Prior to joining Lantheus, Ehlgen served as senior director of clinical affairs for start-up biotechnology company Point Biomedical. In this position, Lantheus said that he was responsible for the clinical development of an ultrasound imaging agent to diagnose coronary artery disease.
Griffin joins Lantheus as director, compensation and benefits from Novartis Vaccines and Diagnostics, where he served as director of U.S. compensation and benefits. At Novartis Vaccines and Diagnostics, he led the transition from the Chiron compensation programs to the Novartis structure, according to the North Billerica, Mass.-based Lantheus.
During her time at Dyax as the director of human resources, Boyer was responsible for administration, benefits and compensation, performance management, employee relations and recruiting, according to Lantheus. Prior to joining Dyax, she held various human resources management positions at Nuance and Avicon.